Introduction 56
The practice of conducting scientific studies with low statistical power has been consistently 57 criticized across academic disciplines (1) (2) (3) (4) (5) . Statistical power is the probability that a study will 58 detect an effect when there is a true effect to be detected. Underpowered studies have a low 59 chance of detecting true effects and have been related to systematic biases including inflated 60 effect sizes and low reproducibility (6, 7) . Low statistical power has been demonstrated, amongst 61 others, in the fields of neuroscience and psychology (4, 8, 9) . For clinical trials in the field of 62 medicine, the issue of sample size evaluation and statistical power is essential since clinical 63 decision making and future research are based on these clinical trials (10, 11). Moreover, low 64 power in clinical trials may be unethical in light of the low informational value from the outset 65 while exposing participants to interventions with possible negative (side) effects (1). Also in 66 medical research statistical power is low (3, 8), but a systematic overview of temporal patterns of 67 power, sample sizes, and effect sizes across medical fields does not exist. In the current study, 68 we provide a comprehensive overview of study power, sample size, and effect size estimates of 69 clinical trials published since 1975 which are included in the Cochrane database of systematic 70 reviews, and analyse emerging trends over time.
71

Materials and Methods
72
Data were extracted and calculated from trials included in published reviews from the second 73 Issue of the 2017 Cochrane Database of Systematic Reviews. Cochrane reviews only include 74 meta-analyses if the methodology and outcomes of the included trials are comparable in cross 75 study populations. Meta-analysis data is available for download in standardized XML-format for 76 those with an institutional Cochrane Library license. We provide open-source software to 77 convert these data and reproduce our entire processing pipeline (15).
78
Trials were selected if they were published after 1974 and if they were included in a meta-79 analysis based on at least five trials. For each individual clinical trial, publication year, outcome 80 estimates (odds or risk ratio, risk difference or standardized mean difference) and group sizes 81 were extracted. The power of individual trials was first calculated for detecting small, medium 82 and large effect sizes (Cohen's d or h of 0.2, 0.5 and 0.8, respectively); (11), based on the sample 83 sizes in both trial arms, using a 5% α threshold. Next, analyses were performed based on the 84 observed effect size from meta-analyses with a p-value below 0.05, irrespective of the p-value of 85 the individual trial; if a meta-analysis has a p-value higher than 0.05, the null-hypothesis "there 86 is no effect" cannot be discarded, and power cannot be computed for absent effects. Given that 87 publication bias inflates meta-analytic effect size estimates (7, 13), this can be considered a 88 conservative approach. All analyses were carried out in R using the 'pwr' package (16).
89
Following minimum recommendations for the statistical power of studies (11), comparisons with 90 a power above or equal to 80% were considered to be sufficiently powered. Study power, group 91 sizes and effect sizes over time were summarised and visualized for all clinical trials. 
Results
93
Data from 137 032 clinical trials were available, from 11 852 meta-analyses in 1918 Cochrane 94 reviews. Of these trials 8.1% had a statistical power of at least 80% (the recommended minimum 95 (11), which we shall denote as 'sufficient power') to detect a small effect (Cohen's d or h 0.2), 96 48% and 81% of trials had sufficient power to detect a moderate (Cohen's d or h 0.5) or large 97 effect (Cohen's d or h 0.8), respectively ( Figure 1 ). This figure shows that there was no 98 difference between trials included in meta-analyses with a p-value below 0.05 and those above 99 this threshold. To compute study power to detect the effect observed in the meta-analysis, we examined the 102 subset of meta-analyses with overall group differences with a p-value <0.05: 78 281 trials 103 (57.1%) from 5903 meta-analyses (49.8%) in 1411 Cochrane reviews (73.6%). All following 104 results are based on this sub-selection of meta-analyses. On average, 12.5% of these trials were 105 sufficiently powered to detect the observed effect size from the respective meta-analysis ( Figure   106 1). The median (interquartile range, IQR) power for the four categories corresponding to Figure   107 1 was 19% (12-37%), 78% (49-98%), 99% (87-100%) and 20% (10-48%), respectively.
108
Between 1975-1979 and 2010-2014 study power increased, with the median rising from 16% 109 (IQR 10-39) to 23% (IQR 12-55) (Figure 2, left) , and the proportion of sufficiently powered 110 studies rose from 9.0% (95% confidence interval (CI) for proportions 7.6-10.6) to 14.7% (95% 111 CI 13.9 -15.5) (Figure 2 , top right). This trend is also seen across medical disciplines 112 ( Supplementary Figure 2) . When the power threshold is set at a minimum of 50% power, the 113 proportion of trials with sufficient power is still low but also rising: from 19.3% (95% CI 17.3- Table   121 1; these remained stable over time (Figure 3) . The standardized effect sizes were small to 122 moderate, with a median Cohen's h of 0.21 (IQR 0.12-0.36) and a median Cohen's d of 0.31 123 (0.19-0.51) (Table 1) ; Supplementary Figure 3 shows the distribution plots for these two uninformative studies is that a lack of an effect due to low power might decrease the interest by 160 other research teams to examine the same effect. A third argument against performing small 161 studies is given in a study by Nuijten and colleagues (7), which indicates that the addition of a 162 small, underpowered study to a meta-analysis may actually increase the bias of an effect size 163 instead of decreasing it.
164
There are several limitations to consider in the interpretation of our results. First, the outcome 165 parameter studied in the meta-analysis may be different than the primary outcome of the original 166 study; it may have been adequately powered for a different outcome parameter. This could result 167 in lower estimates of average power, although it seems unlikely that the average effect size of the 168 primary outcomes is higher than the effect sizes in the Cochrane database. Second, in contrast, 169 effect sizes from meta-analyses are considered to be an overestimation of the true effect because 170 of publication bias (7, 13) . Lastly, in determining the required power for a study a 'one size fits 171 all' principle does not necessarily apply as Schulz & Grimes (14) also argue. However, although 172 conventions are always arbitrary (11) a cut-off for sufficient power at 80% is reasonable.
173
With statistical power consistently increasing over time, our data offer perspective and show that 174 we are heading in the right direction. Nevertheless, it is clear that many clinical trials remain 175 underpowered. Although there may be exceptions justifying small clinical trials, we believe that (5170) 0.31 (0.19-0.51) 0.31 (0.19-0.51) Median effect sizes are computed based on the meta-analysis; every meta-analysis is taken into account once irrespective of the number of included trials. To obtain a meaningful summary statistic, effect sizes were transformed to be unidirectional: the absolute number of risk differences and standardized mean differences was taken, and for (Peto) odds ratios and risk ratio's effects below one were inversed (1 divided by the effect, e.g. an RR of 0.5 becomes 2.0). These transformations only change the direction and not the magnitude of the effect. N = number of meta-analyses (number of included studies) *standard effect size: Cohen's d or h -no standard effect size could be computed due to missing confidence intervals 251
